SpeechATAXIA- a multinational, multilanguage consortia for speech in hereditary ataxias – powered by Redenlab

Redenlab is supporting a new speech focussed consortium for ataxia. SpeechATAXIA is a multi-language, multi-national, multi-ataxia study measuring communication change. Participants are recruited from investigator sites in Australia, New Zealand, Europe, North and South America.

The consortia goals include:
Precisely describe longitudinal changes occurring in speech as disease progresses,
– Identify predictors of progression and discover if critical milestones exist in the disease course,
– Explore how communication decline shapes quality of life and disease management,
– Strengthen genotype-phenotype associations to create disease specific profiles.

The program of research is supported by the Ataxia Global Initiative.

Related Post

  • Posted on 28 November, 2021
    Dr Garcia joins the Redenlab science team to drive its language analytics pipeline for cognitive-linguistic disorders like fronto-temporal dementia. Adolfo...
    • Posted on 21 May, 2021
      Redenlab are proud to support an upcoming randomized parallel group, placebo-controlled, dose-escalation clinical trial in Ataxia Telangiectasia run by Professor...
      • Posted on 15 April, 2021
        Redenlab Inc. are excited to announce securing another clinical trial in Friedreich ataxia. Redenlab are providing speech analytics for a...